10x Genomics, Inc. (NASDAQ:TXG) Insider Sells 4,573 Shares

10x Genomics, Inc. (NASDAQ:TXG) insider Benjamin J. Hindson sold 4,573 shares of the firm’s stock in a transaction on Monday, February 24th. The stock was sold at an average price of $11.07, for a total transaction of $50,623.11. Following the completion of the sale, the insider now owns 335,324 shares of the company’s stock, valued at $3,712,036.68. The trade was a 1.35 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

10x Genomics Stock Performance

10x Genomics stock opened at $10.78 on Friday. 10x Genomics, Inc. has a fifty-two week low of $10.63 and a fifty-two week high of $48.42. The firm’s 50-day simple moving average is $14.07 and its 200 day simple moving average is $16.87. The stock has a market cap of $1.32 billion, a PE ratio of -7.09 and a beta of 1.85.

10x Genomics (NASDAQ:TXG) last announced its earnings results on Wednesday, February 12th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.08). 10x Genomics had a negative return on equity of 25.40% and a negative net margin of 29.90%. As a group, analysts predict that 10x Genomics, Inc. will post -1.43 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of TXG. Capital Performance Advisors LLP bought a new stake in shares of 10x Genomics during the 3rd quarter worth $35,000. Blue Trust Inc. increased its holdings in 10x Genomics by 136.5% during the third quarter. Blue Trust Inc. now owns 1,776 shares of the company’s stock worth $40,000 after buying an additional 1,025 shares during the last quarter. Signaturefd LLC raised its position in 10x Genomics by 424.6% in the fourth quarter. Signaturefd LLC now owns 1,794 shares of the company’s stock worth $26,000 after acquiring an additional 1,452 shares during the period. GF Fund Management CO. LTD. purchased a new position in 10x Genomics in the fourth quarter valued at about $32,000. Finally, Venturi Wealth Management LLC grew its position in shares of 10x Genomics by 1,108.9% during the 3rd quarter. Venturi Wealth Management LLC now owns 2,442 shares of the company’s stock valued at $55,000 after acquiring an additional 2,240 shares during the period. Institutional investors own 84.68% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. Leerink Partners lowered shares of 10x Genomics from an “outperform” rating to a “market perform” rating and dropped their price objective for the company from $25.00 to $12.00 in a report on Thursday, February 13th. Morgan Stanley dropped their price objective on shares of 10x Genomics from $28.00 to $26.00 and set an “overweight” rating on the stock in a report on Friday, February 14th. Barclays dropped their price objective on shares of 10x Genomics from $19.00 to $18.00 and set an “overweight” rating on the stock in a report on Monday, February 10th. Leerink Partnrs lowered shares of 10x Genomics from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 13th. Finally, UBS Group dropped their price objective on shares of 10x Genomics from $20.00 to $14.00 and set a “neutral” rating on the stock in a report on Thursday, February 13th. One analyst has rated the stock with a sell rating, nine have given a hold rating and seven have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $20.57.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.